Product Description
Mechanisms of Action: Peripheral Chemoreceptor Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | Brazil | France | Germany | India | Ireland | Morocco | Pakistan | Peru | Portugal
Approved Indications: None
Known Adverse Events: None
Company: Assistance Publique Hopitaux de Paris
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: COVID-19
Phase 3: COVID-19|Pneumonia|Respiratory Insufficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 22reamedcovid01 | N/A |
Unknown status |
Acute Respiratory Distress Syndrome|Hypoxia |
2022-01-31 |
|
| AIRVM-COVID | P3 |
Completed |
COVID-19|Pneumonia|Respiratory Insufficiency |
2021-10-01 |
|
| Almitrine bismesylate in COVID-19 | P4 |
Unknown status |
COVID-19 |
2021-09-23 |
|
| AIRVM COVID | P3 |
Active, not recruiting |
Pneumonia|COVID-19|Respiratory Insufficiency |
2020-07-28 |